What is Brief History of Amyris Company?

Amyris Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

How did Amyris transform yeast into a business-changing tech?

In the late 2000s Amyris engineered yeast to produce artemisinic acid, enabling scalable antimalarial drug precursors and proving industrial synthetic biology’s promise. The company then shifted to fermenting plant sugars into specialty molecules for cosmetics, flavors and materials.

Founded in 2003 in Emeryville, California, Amyris aimed to use metabolic engineering for cleaner chemical supply. After building consumer brands and B2B partnerships, it faced Chapter 11 in August 2023 and reorganized through 2024–2025, refocusing on core ingredient platforms and selective asset sales; see Amyris Porter's Five Forces Analysis.

Amyris was founded on July 17, 2003, by Jay D. Keasling, Jack D. Newman, Kinkead Reiling, and Neil Renninger, drawing on UC Berkeley and Lawrence Berkeley National Laboratory expertise to engineer microbes for sustainable molecule production. The founders targeted fermentation-based routes to replace petrochemical and volatile agricultural supply chains, combining early grant funding, venture capital, and collaborative scale-up.

Founding Story

The original model emphasized designing engineered yeast, validating fermentation at scale, and monetizing through product sales and technology licensing.

• Founded on July 17, 2003, by Keasling, Newman, Reiling, and Renninger (Amyris founding and founders).
• Early involvement from UC Berkeley and Lawrence Berkeley National Laboratory supported IP and research transfer (Amyris early research and development timeline).
• Initial flagship program: artemisinic acid production funded by a $42.6 million Gates Foundation grant beginning in 2004 with royalty-free terms for malaria-endemic countries (Amyris biotechnology milestones).
• Early financing blended grants and venture capital from investors including Khosla Ventures and Kleiner Perkins to build scale-up infrastructure and patent portfolio (notable investors funding rounds and venture capital).

The name evoked botanical resins and the vision of converting plant sugars to high-value molecules; the company’s R&D-and-licensing business model aimed to couple strain engineering with partner-led fermentation scale-up (Amyris business model evolution and strategic pivots).

For a broader timeline and context, see Brief History of Amyris.

Amyris SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Early Growth and Expansion traces Amyris history from industrial fermentation pilots in Brazil to an IPO and a strategic shift from fuels to specialty ingredients and consumer brands as economics and market conditions evolved.

2006–2010: Commercialization and IPO

Amyris advanced artemisinin precursor development with Sanofi while commercializing Biofene (farnesene) for fuels, lubricants and materials; built pilot and industrial fermentation partnerships in Brazil to use sugarcane feedstock and completed a NASDAQ IPO in September 2010, raising about $85 million.

2011–2015: Pivot to Higher‑Margin Ingredients

Facing biofuels headwinds from lower oil prices and scale-up costs, Amyris shifted to specialty ingredients: launched sugarcane-derived squalane (Neossance), developed hemisqualane and terpenes for flavors & fragrances, and signed multi‑year agreements with Firmenich, Givaudan and IFF while ramping Brotas production to reduce kg costs.

2016–2020: B2B Strength and D2C Incubation

Amyris expanded B2B ingredient sales and incubated direct‑to‑consumer brands including Biossance and Pipette; revenue rose from roughly $68 million in 2017 to over $150 million in 2020 (including collaboration revenue), funded by convertibles and strategic deals amid investor concerns about cash burn and operational complexity.

2021–2022: Rapid Growth, Rising Losses, and Governance Changes

Amyris pursued aggressive top‑line expansion—reporting over $270 million revenue in 2022—by scaling brands, launching new ingredients and deepening collaborations; logistics inflation, marketing and working capital widened losses, producing a GAAP net loss exceeding $700 million in 2022, prompting CFO and board changes and tighter operating discipline as competition from precision‑fermentation peers intensified.

Key milestones in this phase include industrial fermentation scale‑up in Brazil, the 2010 IPO, the Neossance squalane product line, strategic F&F supply agreements, and the incubation of consumer brands—see a focused analysis in Growth Strategy of Amyris for detailed context on Amyris company overview and its business model evolution.

Amyris PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

A concise Milestones, Innovations and Challenges chapter covering Amyris history, key biotech milestones, shifts from fuels to specialty ingredients, major partnerships, consumer-brand build and the 2023 Chapter 11 restructuring through 2024–2025 refocusing on fermentation IP and B2B ingredients.

Amyris innovations included commercialization of an artemisinin precursor (Sanofi circa 2013–2014) and development of Biofene (farnesene) enabling multiple derivatives across flavors, fragrances, cosmetics and materials. The Neossance squalane launch moved cosmetic supply chains toward bio-based squalane, and partnerships with Givaudan, IFF and Firmenich/dsm-firmenich scaled offtake and validation.

Artemisinin precursor

Commercialized by Sanofi circa 2013–2014, this synbio-produced precursor became a landmark for health-focused synthetic biology and demonstrated industrial biotech impact on pharmaceuticals.

Biofene (farnesene) platform

Engineered yeast produced farnesene at scale for fragrance and emollient derivatives; patents covered metabolic pathways, strain optimization and downstream processing.

Neossance squalane

Bio-based squalane provided a sustainable alternative to shark- and olive-derived sources, and by the early 2020s Amyris claimed leadership in supply to global beauty brands.

F&F strategic agreements

Offtake and validation agreements with Givaudan, IFF and Firmenich/dsm-firmenich enabled commercial adoption of specialty ingredients.

Vertical integration to consumer brands

Owned brands such as Biossance and Pipette demonstrated end-to-end capability from microbe to shelf and aimed to capture downstream margins.

IP and licensing

Patent portfolio covered key pathway engineering and processing technologies, supporting licensing and toll-manufacturing revenue streams; see Revenue Streams & Business Model of Amyris.

Key challenges included unfavorable biofuels economics that prompted a 2012–2015 pivot to specialty ingredients, and the capital intensity of scaling fermentation to meet cost and yield targets. Rising SG&A for consumer brand growth, supply-chain shocks in 2020–2022, and elevated ad spend led to recurring negative operating cash flow and the August 2023 Chapter 11 filing.

Fuel-to-specialty pivot

Low-margin biofuels could not compete with petrochemicals, prompting strategic redirection to higher-margin specialties and ingredients.

Scaling and capex

Achieving consistent yields required substantial capex and process development time, delaying margin improvement and increasing cash burn.

Brand economics

Investing in owned consumer brands raised SG&A and marketing spend, pressuring operating cash flow and liquidity when sales growth slowed.

Restructuring and divestiture

Chapter 11 in August 2023 addressed liabilities > $1,000,000,000, leading to asset sales (Biossance, JVN, Rose Inc.) and refocus on B2B fermentation and licensing.

Industry lesson

The company trajectory reflects a broader synbio lesson: platform innovation must pair with disciplined capital allocation and defensible unit economics to achieve sustainable growth.

Post-2024 direction

After divestitures, Amyris emphasizes fermentation IP, toll manufacturing and licensing as core revenue drivers while reducing fixed-cost exposure.

Amyris Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Timeline and Future Outlook of the Amyris company overview: concise timeline from founding in 2003 through the 2024–2025 post-reorg pivot back to B2B ingredients, highlighting key milestones, financings, product pivots, Chapter 11 and the capital-light manufacturing strategy aimed at profitable ingredients growth.

Strategic focus

Priority on becoming a capital-light ingredients provider selling squalane, hemisqualane and specialty terpenes via long-term offtake agreements with F&F and beauty majors.

Manufacturing approach

Leverage Brazilian sugarcane economics at Brotas and third-party fermentation partners to minimize capex and improve unit economics.

Market and regulatory trends

Growing demand for sustainable, traceable inputs and regulatory momentum on deforestation-free, low-carbon materials support synthetic biology adoption.

Financial targets

Targeting positive operating cash flow through reduced brand overhead, tighter SG&A and a higher-margin B2B revenue mix, with monetization of IP and licensing.

Leadership communications during restructuring stressed returning to core competencies and scalable ingredients growth; success will depend on disciplined portfolio selection, recurring B2B contracts and improving techno-economics in precision fermentation—see further context in Target Market of Amyris.

Amyris Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔